Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.
Giles Robinson(St. Jude Children's Research Hospital), Ami V. Desai(University of Chicago Medical Center), Luke Maese(University of Utah), Amit J. Sabnis(University of California, San Francisco), Amar Gajjar(St. Jude Children's Research Hospital), Brian Weiss(Cincinnati Children's Hospital Medical Center), Janet Yoon(University of California San Diego), Karen Gauvain(Washington University in St. Louis), Mufiza Farid‐Kapadia(Roche (Canada)), Elizabeth Fox(Children's National), Alison K. Cardenas, Margaret E. Macy(Children's Hospital Colorado), Jennifer H. Foster(Children's Cancer Center), Suzanne Shusterman(Dana-Farber Cancer Institute), Guillaume Bergthold(Roche (Switzerland)), Georgina Meneses‐Lorente(Roche (United Kingdom)), Mohamed S Abdelbaki(Nationwide Children's Hospital), Edna Chow Maneval(Dana (United States)), Katherine E. Hutchinson(Vanderbilt University), Ellen M. Basu(Memorial Sloan Kettering Cancer Center)
Cited by 61
Related Papers
Novel mutations target distinct subgroups of medulloblastoma
|Nature|2012|853
Integrated Molecular Genetic Profiling of Pediatric High-Grade Gliomas Reveals Key Differences With the Adult Disease
|Journal of Clinical Oncology|2010|657
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus
|Acta Neuropathologica|2016|650
Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling
|Science Translational Medicine|2011|530